Welcome to our dedicated page for Cerus news (Ticker: CERS), a resource for investors and traders seeking the latest updates and insights on Cerus stock.
Cerus Corporation (CERS) is a pioneering biomedical products company dedicated to enhancing blood safety worldwide. The company’s flagship technology, the INTERCEPT Blood System, aims to mitigate the risk of transfusion-transmitted diseases by inactivating a broad spectrum of pathogens, including viruses, bacteria, and parasites present in donated blood. Utilizing a unique nucleic acid targeting mechanism, the INTERCEPT system offers protection against established threats like Hepatitis B and C, HIV, West Nile Virus, and bacteria, while also being designed to inactivate emerging pathogens such as Influenza, Malaria, and Dengue.
Cerus Corporation markets and sells the INTERCEPT Blood System for both platelets and plasma in various regions including Europe, Russia, the Middle East, and selected countries globally. The INTERCEPT Red Blood Cell system is currently in clinical development, highlighting the company’s ongoing efforts to broaden its product offerings and enhance blood safety further.
Recent achievements for Cerus include expanding market reach, securing regulatory approvals, and forging key partnerships to strengthen its global presence. Financially, Cerus remains focused on sustaining growth through innovation and strategic collaborations.
By prioritizing safety and efficacy, Cerus Corporation plays a critical role in the field of blood transfusion safety, making significant strides in protecting public health on a global scale.
Cerus (Nasdaq: CERS) has announced that its Chief Financial Officer, Kevin Green, will participate in the 21st Annual Craig-Hallum Institutional Investor Conference. The event will take place in Minneapolis on Wednesday, May 29th. This participation is a significant opportunity for Cerus to discuss its financial health and future outlook with key institutional investors.
Cerus (Nasdaq: CERS) reported a 24% increase in product revenue for the first quarter of 2024, reaching $38.4 million. The company also achieved FDA approval for extended shelf life of INTERCEPT Platelet Processing Sets and advanced its LED illuminator program. Cash and cash equivalents were $72.2 million, with a full-year 2024 product revenue guidance range of $172 million to $175 million.
FAQ
What is the current stock price of Cerus (CERS)?
What is the market cap of Cerus (CERS)?
What is Cerus Corporation's main focus?
What pathogens does the INTERCEPT Blood System target?
Where is the INTERCEPT Blood System marketed?
What products does Cerus Corporation offer?
What are some recent achievements of Cerus Corporation?
How does the INTERCEPT Blood System work?
What financial strategies does Cerus Corporation employ?
Is Cerus Corporation involved in research for emerging pathogens?
What regions are key markets for Cerus Corporation?
What segment does Cerus Corporation operate in?
